THEIR

HURTS

Discover unspoken trade-offs in managing hemophilia A^1,2

Are your patients compromising bleed protection or accepting administration-related challenges?

Nikola lives with Hemophilia A

^aBased on a real-world study with 354 people with hemophilia A. Analysis is limited to ABRs in medical records and PROs from the survey and may have been limited by medical record discrepancies, recall bias, and potential reporting bias for bleeds.³

ABR=annual bleed rate; PROs=patient-reported outcomes.

EXAMINE THE CLINICAL EVIDENCE

Do breakthrough bleeds persist
despite prophylaxis?

See the data

What administration challenges
may be holding patients back?

Discover real experiences

How can deeper conversations
lead to uncovering patient truths?

Uncover the impact

HOW ARE TREATMENT
APPROACHES EVOLVING?

Researchers are investigating ways to simultaneously improve bleed protection and reduce administration challenges.²

Explore treatment approaches

David lives with Hemophilia A

IT IS IMPORTANT TO TAKE A DEEPER LOOK

People living with hemophilia A may be making trade-offs by compromising bleed protection or accepting administration-related challenges, which can negatively impact their lifestyle.^1-3

ARE YOUR PATIENTS STRUGGLING WITH BREAKTHROUGH BLEEDS?

See results from real-world studies

Go now

STAY UP TO DATE
WITH THE LATEST INFORMATION

Get updates and communications on hemophilia A from Novo Nordisk as they become available.

References

Wheeler AP, Cibelli E, Hanson G, et al. Treatment and disease burden in a cohort of people with haemophilia without inhibitors in the United States. Haemophilia. 2025;31(5):912-921.
Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition [published correction appears in Haemophilia. 2021;27(4):699]. Haemophilia. 2020;26(suppl 6):1-158.
Data on file. Novo Nordisk Inc; Plainsboro, NJ

THEIR

HURTS

Discover unspoken trade-offs in managing hemophilia A1,2